ReviewCurrent heart failure reports2020
Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
Review in Current heart failure reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Systolic blood pressure lower than 130 mmHg in heart failure with preserved ejection fraction: a systematic review and meta-analysis of clinical outcomes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- The value of urinary sodium assessment in acute heart failure.European heart journal. Acute cardiovascular care · 2021Pooled it
- Association of Angiotensin Receptor-Neprilysin Inhibitors Use and Better Cardiorenal Outcomes in Patients With Heart Failure and Acute Kidney Disease.Cardiovascular drugs and therapy · 2026Observational
- Takayasu arteritis-associated refractory hypertension induces nephrotic syndrome through glomerular microangiopathy.CEN case reports · 2025Article
- Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Behcet's disease presenting as malignant hypertension induced by renovascular hypertension.CEN case reports · 2025Article
- Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: A comparative review.Frontiers in pharmacology · 2023Review
- Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach.Frontiers in physiology · 2022Review
- Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.Kidney research and clinical practice · 2021Article
- Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- Renal protection in chronic heart failure: focus on sacubitril/valsartan.European heart journal. Cardiovascular pharmacotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide pathophysiological and clinical insights into the effects of sacubitril/valsartan on glomerular function. RECENT
findingsHeart failure and glomerular dysfunction are closely intertwined. In addition to reduced heart failure hospitalization and all-cause mortality, patients treated with sacubitril/valsartan have a slower deterioration of glomerular filtration rate over time compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. The effects of sacubitril/valsartan are probably mediated through enhancement of natriuretic peptides, reduction of glomerular inflammation and fibrosis, and relaxation of mesangial cells and podocytes. Further studies will elucidate underlying pathophysiological mechanisms of sacubitril/valsartan on glomerular function and their prognostic significance in subjects with and without heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.